Loading...
By the Editors
The FDA has approved the first generic version of the asthma and chronic obstructive pulmonary disease (COPD) inhaler Advair Diskus (fluticasone propionate and salmeterol inhalation powder).
The generic inhaler is approved to treat asthma in patients aged 4 years and older and to manage airflow obstruction and reduce exacerbations associated with COPD.
Comment
LINK(S):
FDA news release (Free)
Background: NEJM Journal Watch Pediatrics and Adolescent Medicine coverage of fluticasone/salmeterol for treating asthma in children (Your NEJM Journal Watch registration required)